| Name | Title | Contact Details |
|---|
For over 120 years, Parr Instrument Company has been designing, manufacturing, and selling high quality laboratory instruments and apparatus for conducting chemical reactions and tests under heat and pressure and for testing fuels. Parrs extensive product line includes stirred reactors, pressure vessels, and high pressure tubular reactors for the study of catalytic and non-catalytic reactions in batch, continuous-flow, and multiple/parallel operation for the chemical, polymer, biofuels, hydrometallurgical, pharmaceutical, petroleum, and petrochemical industries. Custom designed complex reactor systems, built to the customers specifications and requirements are also provided. Parrs oxygen combustion calorimeters are used for the determination of the heat of combustion in solid, liquid, and refuse-derived fuels for the energy, educational, coal, and fuel testing industries. Parr also offers sample preparation vessels for extraction, digestion, and hydrothermal synthesis, as well as a line of vessels for cell disruption by nitrogen decompression.
American Repertory Ballet (ARB) and; ARBs Princeton Ballet School. New Jerseys leading contemporary ballet company, and the States largest ballet school.
Invisible is the operations innovation company transforming how companies are built and run. Our tech-enabled service harnesses our proprietary process orchestration platform, which seamlessly blends AI and automation with a global team of over 2000 highly-skilled agents. This integration eliminates execution bottlenecks and opens up new efficiency, scale, and growth possibilities for clients, delivering any operations capability better, faster, and cheaper than traditional 20th century services companies.
MITY Incorporated is a worldwide leader in helping customers optimize their facilities with innovative furniture solutions. Our product brands MityLite®, Holsag®, Bertolini®, and XpressPort®. The products manufactured by our brands deliver the safety, ease of use, and functional design needed for businesses in industries such as hospitality, worship, education, senior living, restaurant, and government. With worldwide headquarters in Orem, Utah operating since 1987, MITY now has offices and manufacturing facilities in Tennessee, Missouri, and Ontario. QUALITY ENGINEERING: Detailed design and superior manufacturing go into every product built by MITY product brands. We stand by our strong warranty program and commitment to excellent customer service. INNOVATIVE PRODUCTS: ABS Folding Tables, stacking banquet chairs, folding chairs, portable dance floors, mobile banquet tables, and linenless tables with integrated power—we offer the best! OUR SECRET SAUCE: We have the most elite, creative, and passionate team of employees in the industry! They are committed to serving our business partners. Interested in joining our team or doing business with MITY? Email info@mityinc.com or call 800-909-8034.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.